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Identity 
Other names: MMAC1 (Mutated in Multiple 
Advanced Cancer 1); TEP 1 (TGFb regulated and 
Epithelial cell enriched Phosphatase 1) 
HGNC (Hugo): PTEN 
Location: 10q23.3 
Local order: between D10S1765 and D10S541. 
DNA/RNA 
Description 
9 exons, all coding; exon 1 has an unusually long 5' 
untranslated GC-rich region; exon 5 codes for the 
phosphatase core motif. 
Transcription 
2 major detected transcripts; respectively 2 and 5 kb; 
open reading frame : 1209 bp. 
Protein 
Description 
403 aminoacids, 47 kDa; N-terminal phosphatase 
domain (from a.a. 1 to 185) with the catalytic core 
motif between; a.a. 123-131 encoded by exon 5; C-
terminal PDZ binding domain. 
Localisation 
Cytoplasmic localization (immunohistochemistry). 
Function 
Phosphatase activity; substrate: phosphatidylinositol 
3,4,5-tri phosphate (PIP3);  
PTEN appears as a negative regulator of the PI3K/AKT 
signaling pathway; It is unclear if PTEN is able to 
dephosphorylate a protein substrate in vivo; tumor 
suppressive function: biallelic inactivation is observed 
in several tumor-types and inactivating germline 
mutations are responsible for a cancer prone syndrome, 
the Cowden disease; anti-invasive and anti-proliferative 
effects were documented in several cell lines. 
Mutations 
Germinal 
Germline mutations have been documented in Cowden 
disease and in Bannayan, Riley, Ruvalcaba phenotype 
(see below); they are observed along the various exons 
of the gene except the 9th (never described) and the 1st 
(very few reports); a mutational hot spot is observed in 
exon 5 in relation with the catalytic core motif; in the 
great majority of the cases, inactivating mutations are 
observed, either by protein truncation, or by misense 
mutation within the phosphatase domain. 
Somatic 
Mutations are observed in several tumor type; they lead
to a biallelic inactivation of the gene either by 
homozygous deletion, or by a combination of point 
mutation and a large deletion of the second allele. 
Implicated in 
Cowden disease and Bannayan, Riley, 
Ruvalcaba phenotype 
Disease 
Cowden disease is also known as multiple hamartoma 
syndrome, a cancer prone condition with autosomal 
dominant pattern of inheritance and high susceptibility 
to breast carcinoma and in a less extent to thyroid 
carcinoma; Bannayan, Ryley, Ruvalcaba syndrome 
correspond to the pediatric contrepart of Cowden 
disease with phenotypic overlap between the 2 
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syndromes (macrocephaly, intestinal polyps, lipomas, 
genital pigmented macules). 
Sporadic malignant tumors 
Disease 
Somatic mutations were observed mainly in 
glioblastoma and in endometrial carcinoma, about 30% 
of these two kinds of tumors showing point mutations; 
only a few mutations were reported in prostate 
carcinoma, malignant melanoma, non Hodgkin 
lymphomas, breast carcinoma. 
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